All 1 tracked stories fall under one category: pharma. AeroDel is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 runs below the beat's 6.4 for that window. They are better corroborated than the beat average, carrying 3 original sources each against 2.8 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Aerolife Mini
All 1 tracked stories fall under one category: pharma. AeroDel is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 runs below the beat's 6.4 for that window. They are better corroborated than the beat average, carrying 3 original sources each against 2.8 for the same window. We currently track 1 Biotech story that mention Aerolife Mini, all published on March 20, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Aerolife Mini. Shared-story counts are live from our verified record — not editorial picks.
AeroDel has entered into an exclusive licensing agreement with Zydus Lifesciences to launch Aerolife Mini, a first-of-its-kind foldable and permanently attached pMDI enhancer in India. This device aims to improve medication delivery and patient adherence for respiratory conditions like asthma and COPD by addressing the portability issues of traditional spacers.
Aerolife Mini is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.